vs
Side-by-side financial comparison of IDEAYA Biosciences, Inc. (IDYA) and SIMMONS FIRST NATIONAL CORP (SFNC). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $197.3M, roughly 1.1× SIMMONS FIRST NATIONAL CORP). SIMMONS FIRST NATIONAL CORP produced more free cash flow last quarter ($411.4M vs $142.2M).
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
Simmons Bank is a bank with operations in Arkansas, Kansas, Missouri, Oklahoma, Tennessee, and Texas. It is the primary subsidiary of Simmons First National Corporation, a bank holding company.
IDYA vs SFNC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $207.8M | $197.3M |
| Net Profit | $119.2M | — |
| Gross Margin | — | — |
| Operating Margin | 52.2% | — |
| Net Margin | 57.4% | — |
| Revenue YoY | — | 19.6% |
| Net Profit YoY | 330.1% | — |
| EPS (diluted) | $1.33 | $0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $197.3M | ||
| Q3 25 | $207.8M | $186.7M | ||
| Q2 25 | — | $214.2M | ||
| Q1 25 | — | $209.6M | ||
| Q4 24 | — | $208.5M | ||
| Q3 24 | $0 | $174.8M | ||
| Q2 24 | $0 | $197.2M | ||
| Q1 24 | $0 | $195.1M |
| Q4 25 | — | — | ||
| Q3 25 | $119.2M | $-562.8M | ||
| Q2 25 | — | $54.8M | ||
| Q1 25 | — | $32.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-51.8M | $24.7M | ||
| Q2 24 | $-52.8M | $40.8M | ||
| Q1 24 | $-39.6M | $38.9M |
| Q4 25 | — | — | ||
| Q3 25 | 52.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 57.4% | -301.5% | ||
| Q2 25 | — | 25.6% | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 14.1% | ||
| Q2 24 | — | 20.7% | ||
| Q1 24 | — | 19.9% |
| Q4 25 | — | $0.36 | ||
| Q3 25 | $1.33 | $-4.00 | ||
| Q2 25 | — | $0.43 | ||
| Q1 25 | — | $0.26 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | $-0.60 | $0.20 | ||
| Q2 24 | $-0.68 | $0.32 | ||
| Q1 24 | $-0.53 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $786.9M | — |
| Total DebtLower is stronger | — | $620.0M |
| Stockholders' EquityBook value | $1.1B | $3.4B |
| Total Assets | $1.2B | $24.5B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $786.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $920.0M | — | ||
| Q2 24 | $701.7M | — | ||
| Q1 24 | $698.8M | — |
| Q4 25 | — | $620.0M | ||
| Q3 25 | — | $667.8M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.2B |
| Q4 25 | — | $3.4B | ||
| Q3 25 | $1.1B | $3.4B | ||
| Q2 25 | — | $3.5B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | — | $3.5B | ||
| Q3 24 | $1.2B | $3.5B | ||
| Q2 24 | $931.7M | $3.5B | ||
| Q1 24 | $935.3M | $3.4B |
| Q4 25 | — | $24.5B | ||
| Q3 25 | $1.2B | $24.2B | ||
| Q2 25 | — | $26.7B | ||
| Q1 25 | — | $26.8B | ||
| Q4 24 | — | $26.9B | ||
| Q3 24 | $1.2B | $27.3B | ||
| Q2 24 | $973.7M | $27.4B | ||
| Q1 24 | $961.5M | $27.4B |
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | 0.20× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $142.2M | $449.5M |
| Free Cash FlowOCF − Capex | $142.2M | $411.4M |
| FCF MarginFCF / Revenue | 68.4% | 208.5% |
| Capex IntensityCapex / Revenue | 0.0% | 19.3% |
| Cash ConversionOCF / Net Profit | 1.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | $13.5M | $717.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $449.5M | ||
| Q3 25 | $142.2M | $223.4M | ||
| Q2 25 | — | $77.6M | ||
| Q1 25 | — | $32.8M | ||
| Q4 24 | — | $425.9M | ||
| Q3 24 | $-49.2M | $199.4M | ||
| Q2 24 | $-32.9M | $86.1M | ||
| Q1 24 | $-43.8M | $57.6M |
| Q4 25 | — | $411.4M | ||
| Q3 25 | $142.2M | $216.7M | ||
| Q2 25 | — | $66.3M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | — | $380.4M | ||
| Q3 24 | $-49.7M | $187.7M | ||
| Q2 24 | $-33.9M | $72.7M | ||
| Q1 24 | $-45.1M | $47.7M |
| Q4 25 | — | 208.5% | ||
| Q3 25 | 68.4% | 116.1% | ||
| Q2 25 | — | 31.0% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 182.5% | ||
| Q3 24 | — | 107.4% | ||
| Q2 24 | — | 36.9% | ||
| Q1 24 | — | 24.5% |
| Q4 25 | — | 19.3% | ||
| Q3 25 | 0.0% | 3.6% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | — | 6.7% | ||
| Q2 24 | — | 6.8% | ||
| Q1 24 | — | 5.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.06× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
